It may well be dark days for the share market with the ASX200 down an eye-watering 6% at the open, but Challenger (ASX: CFG) has defied the downdraft on news that TAL Dai-ichi Life Australia Pty Limited (TAL) has acquired a significant stake in its operation.
Shares in Challenger were up around 10% at the open following revelations that TAL Dai-ichi Life – a subsidiary of Tokyo-listed Dai-ichi Life - has acquired MS&AD Holdings’ 15.1% stake in the retirement product provider and fund manager, subject to FIRB and APRA approvals.
The deal was priced at $8.74 a share – or a 58% premium to the last closing price.
Challenger's CEO Nick Hamilton told the market that the company is looking forward to building a relationship that will benefit both customers and shareholders.
“This is an exciting time for Challenger as we deliver our growth strategy and provide financial confidence to even more Australians in retirement,” said Hamilton.
Will a TAL bid follow?
Given the inherent operating synergies between life insurance and annuities, market speculators have been quick to speculate about a future takeover bid by TAL for Challenger.
However, to pour cold water on market rumours, TAL has stated that it had “no current intention” to takeover Australia’s largest annuity company which at 31 December 2024 managed $25 billion in assets.
However, TAL's previous corporate activity suggests otherwise.
Investors should note that TAL typically advances a total takeover offer once it acquires a sizeable stake in a company.
Equally noteworthy, the premium at which TAL acquired its stake in Challenger hints at the value it ascribes to the business.
With the Challenger share price trading at a 23% discount to its 52-week high, TAL may have concluded that the time to stage a takeover may not get any better than now.
Diversification and scale
TAL acquired Suncorp’s Australian Life Insurance business in 2019, and in the face of limited growth opportunities within the domestic market, has been looking to diversify its earnings via overseas expansion.
Further plans are being made to scale up TAL's asset management and employee benefits platforms.
Challenger’s share price fell 9% after reporting $225 million in normalised net profit after tax for 1H FY25, up 12% due to higher earnings in its Life and Funds Management businesses and holds $131 billion in assets under management.
While retail investors are still attracted to the stock, institutional investors are wary of buying into ASX200 stock. Major shareholder, Wall Street asset manager Apollo Management, has halved its stake to 9.9% from 20.12% in September.
Overhang
Meanwhile, Apollo Management’s remaining 9.9% stake in Challenger had created something of an overhang, and given this, it most probably wanted out.
This overhang may quickly disappear given TAL surfaces with a takeover offer. However, a TAL bid for Challenger may flush out other suitors, and pan-Asian insurer AIA has also been eyeballing the stock for some time.
Meanwhile, Challenger said the share sale would not impact its current reinsurance partnership with MS&AD subsidiary Mitsui Sumitomo Primary Life Insurance.
Bank of America advises TAL, while Jarden and Goldman Sachs are advising Challenger.
Challenger has a market cap of $4.1 billion making it the 110th largest stock on the ASX. The share price is down 14% in one year and up 8% in the last month.
The stock appears to have completed a medium-term rally that took the 5-day moving average above the 50-day moving average and will likely continue its bearish trend.
Consensus is Strong Buy
This article does not constitute financial or product advice. You should consider independent advice before making financial decisions.
